Regulatory Consultant

Erika Ross Ellison is President of the IEEE Engineering in Medicine & Biology Society (EMBS), leading a global community of 14,000 bioengineers across nearly 100 countries. She is also Founder of Ross Ellison Consulting, where she advises early-stage neurotechnology companies on clinical, regulatory, and quality strategy and serves as a fractional Chief Clinical & Regulatory Officer for companies such as Neuraworx Medical. 

Previously, Erika was Vice President of Global Clinical, Regulatory, and Quality at ONWARD Medical, guiding the company’s neuromodulation therapies for spinal cord injury through FDA market authorization (2024) and CE Mark approval (2025). Earlier, she served as Director of Clinical & Applied Research at Abbott, advancing neuromodulation treatments for Parkinson’s disease and chronic pain, and as Neuroscience Director at Cala Health, a Stanford Biodesign-incubated startup, where she helped build the company’s digital health architecture and commercialization strategy.

Her career began at Mayo Clinic as Assistant Professor of Neurologic Surgery and Deputy Director of the Surgical Device Innovation Accelerator, where she developed neuromodulation technologies, surgical innovations, and led DARPA-funded neuroplasticity projects.

Erika earned her B.S. in Biology and Neuroscience and M.S. in Molecular Biology from the University of Denver, and her Ph.D. in Neuroscience (Neural Engineering, Deep Brain Stimulation focus) from the Mayo Clinic.